3334 East Coast Hwy 157
Corona del Mar
51 articles with CureDuchenne
CureDuchenne, a leading global nonprofit dedicated to finding and funding a cure for Duchenne muscular dystrophy, is celebrating Dyne Therapeutics' successful initial public offering and subsequent listing on NASDAQ.
CureDuchenne Ventures Announces The "CureDuchenne Ventures 2020 Pitch Contest," To Award Two $25,000 Prizes For Novel Ideas In Duchenne Muscular Dystrophy Therapy Development
CureDuchenne Ventures, the venture funding arm of CureDuchenne, a leading global nonprofit dedicated to funding and finding a cure for Duchenne muscular dystrophy, announced the first ever CureDuchenne Ventures 2020 Pitch Contest.
CureDuchenne Applauds Pfizer’s Encouraging Data from Phase Ib Mini-Dystrophin Gene Therapy Trial for Duchenne Muscular Dystrophy
CureDuchenne, a leading global nonprofit focused on funding and finding a cure for Duchenne muscular dystrophy, congratulates Pfizer for announcing data from subjects that have completed the 12 month Phase Ib clinical trial presented at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. Today’s announcement included updates on the safety and efficacy data from muscle biopsies and the North
CureDuchenne Continues Focus as Champions for the Duchenne Community with Launch of Innovative Suite of Online Resources
CureDuchenne, the leading global nonprofit focused on funding and finding a cure for Duchenne muscular dystrophy, is rolling out a comprehensive suite of online resources for the Duchenne community. This suite of resources is aimed at engaging the community to maintain continuity of care and community building in the current times of global health uncertainty: Coronavirus Health Update Guide
Global Research Nonprofit CureDuchenne Joins Pfizer to Host Free Webinar on Pfizer’s Advancement to Phase III Gene Therapy Clinical Trial
CureDuchenne, the leading global nonprofit focused on finding a cure for Duchenne muscular dystrophy, will co-host a free webinar with Pfizer to discuss their advancement to Phase III Clinical Trial for PF-06939926.
Hundreds gathered at the Monarch Beach Resort on Saturday, February 29 to enjoy the best of Napa Valley wineries and help find a cure for Duchenne muscular dystrophy.
UCI and RUCDR Infinite Biologics partner in establishing an important resource for translational medicine that is accessible to researchers worldwide.
CureDuchenne Invests in Chameleon Biosciences to Support EVADER™, a Next Generation Adeno Associated Virus Based Gene Therapy Platform Technology
Investment will help advance development of the only gene therapy technology offering resistance to pre-existing antibodies, enhanced gene delivery and the potential for repeat dosing.
CureDuchenne, a leading nonprofit in Duchenne research, patient care and innovation, announced its line-up of CureDuchenne Cares events that will take place across the United States in 2020.
CureDuchenne announced it has tapped Erin Frey as Senior Director of Advocacy.
Nonprofit CureDuchenne is Encouraged to See Gene Editing for Duchenne Advance Through Vertex’s Acquisition of Exonics Therapeutics
Deal will accelerate drug development for Duchenne muscular dystrophy, a rare disease that affects 300,000 boys and young men worldwide
Investment advances pre-clinical development of novel exon skipping therapies for treatment of patients with Duchenne muscular dystrophy
CORRECTING and REPLACING CureDuchenne Ventures Commits $500,000 to 4D Molecular Therapeutics to Advance Next-Generation AAV Delivery of Gene Therapy
A multimedia asset accompanying this release has been removed.
Dedicated Online Platform DuchenneXchange.org Launches to Unite, Support and Educate Duchenne Community
The Duchenne muscular dystrophy (DMD) community now has a dedicated online platform where they can connect and share knowledge - DuchenneXchange (DuchenneXchange.org)
Sarepta Therapeutics, Inc. and CureDuchenne to Host Webinar on Duchenne Muscular Dystrophy Programs Utilizing Sarepta’s RNA-Targeted Technology Platforms
Sarepta Therapeutics, Inc. and non-profit CureDuchenne announced today they have partnered to host a free webinar to provide Duchenne muscular dystrophy patients, caregivers and advocates a comprehensive review of Sarepta’s RNA-targeted technology platforms (PMO and PPMO).
CureDuchenne, a nonprofit dedicated to funding research and improving patient care for Duchenne muscular dystrophy, launched the CureDuchenne Cares Virtual Durable Medical Equipment (DME) Expo as a resource for the Duchenne community.
CureDuchenne Release: 7th Annual Getzlaf Golf Shootout Raises More Than $546,000 To Help Find A Cure For Duchenne Muscular Dystrophy
CureDuchenne Continues To Support Research For Duplication Mutations In Duchenne With Dr. Flanigan From Nationwide Children’s Hospital, And With A Coalition Of Families Impacted By The Disease
Anaheim Ducks Captain Ryan Getzlaf Supports CureDuchenne In 7th Annual Getzlaf Golf Shootout To Help Saves Lives Of Those With Duchenne